Why the study?
Does phenelzine improve depression compared to placebo and amitriptyline, and is efficacy dependent on the degree of MAO inhibition in depressed patients?
Does phenelzine improve depression compared to placebo and amitriptyline, and is efficacy dependent on the degree of MAO inhibition in depressed patients?
The clinical efficacy of phenelzine in treating depression is highly correlated with achieving at least 80-90% inhibition of platelet MAO activity.
This is the authors' abstract. We don't add key points for this paper.
This report examines the hypothesis that for phenelzine to be more effective than placebo it is necessary to achieve at least 80% inhibition of platelet MAO activity. This hypothesis was examined in the context of a double-blind comparison of phenelzine, amitriptyline and placebo in depressed patients. When phenelzine became significantly more effective than placebo at 4 weeks, the average MAO inhibition was 85%. By the 5th week, with MAO inhibition greater than 90%, phenelzine was significantly more effective than amitriptyline. A highly significant correlation was noted between improvement and MAO inhibition within the phenelzine group.
Answers are grounded in this paper and cite their sources.
Supports MAO inhibition monitoring to optimize phenelzine dosing in depression; confirms threshold-dependent efficacy in RCT evidence.
No takes yet. Share an insight, caveat, or question.
Raft et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: